AHAndrew M. Hall

Andrew M. Hall

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andrew M. Hall has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Effective antigen presentation to helper T cells by human eosinophils

    by Ruhaifah K. Farhan, Mark A. Vickers, Amir M. Ghaemmaghami, Andrew M. Hall, Robert N. Barker, Garry M. Walsh

    Summary: Although eosinophils are inflammatory cells, there is increasing attention on their immunomodulatory roles. For example, murine eosinophils can present antigen to CD4+ T helper (Th) cells, but it remains unclear whether human eosinophils also have this ability. This study determined whether human eosinophils present a range of antigens, including allergens, to activate Th cells, and characterized their expression of MHC class II and co‐stimulatory molecules required for effective presentation. Human peripheral blood eosinophils purified from non‐allergic donors were pulsed with the antigens house dust mite extract (HDM), Timothy Grass extract (TG) or Mycobacterium tuberculosis purified protein derivative (PPD), before co‐culture with autologous CD4+ Th cells. Proliferative and cytokine responses were measured, with eosinophil expression of HLA‐DR/DP/DQ and the co‐stimulatory molecules CD40, CD80 and CD86 determined by flow cytometry. Eosinophils pulsed with HDM, TG or PPD drove Th cell proliferation, with the response strength dependent on antigen concentration. The cytokine responses varied with donor and antigen, and were not biased towards any particular Th subset, often including combinations of pro‐ and anti‐inflammatory cytokines. Eosinophils up‐regulated surface expression of HLA‐DR/DP/DQ, CD80, CD86 and CD40 in culture, increases that were sustained over 5 days when incubated with antigens, including HDM, or the major allergens it contains, Der p I or Der p II. Human eosinophils can, therefore, act as effective antigen‐presenting cells to stimulate varied Th cell responses against a panel of antigens including HDM, TG or PPD, an ability that may help to determine the development of allergic disease.


  • Open Access

    Combination peptide immunotherapy suppresses antibody and helper T-cell responses to the RhD protein in HLA-transgenic mice

    by L. S. Hall, A. M. Hall, W. Pickford, M. A. Vickers, S. J. Urbaniak, R. N. Barker

    The offspring from pregnancies of women who have developed anti-D blood group antibodies are at risk of hemolytic disease of the newborn. We have previously mapped four peptides containing immunodominant T-helper cell epitopes from the RhD protein and the purpose of the work was to develop these into a product for suppression of established anti-D responses. A panel of each of the four immunodominant RhD peptides was synthesized with modifications to improve manufacturability and solubility, and screened for retention of recognition by human T-helper cells. A selected version of each sequence was combined in a mixture (RhDPmix), which was tested for suppressive ability in a humanized murine model of established immune responses to RhD protein. After HLA-DR15 transgenic mice had been immunized with RhD protein, a single dose of RhDPmix, given either intranasally (P=0.008, Mann-Whitney rank sum test) or subcutaneously (P=0.043), rapidly and significantly suppressed the ongoing antibody response. This was accompanied by reduced T-helper cell responsiveness, although this change was less marked for subcutaneous RhDPmix delivery, and by the recruitment of cells with a regulatory T-cell phenotype. The results support human trials of RhDPmix peptide immunotherapy in women with established antibody responses to the RhD blood group.


  • Open Access

    Expansion of Foxp3+ T‐cell populations by Candida albicans enhances both Th17‐cell responses and fungal dissemination after intravenous challenge

    by Natasha Whibley, Donna M. MacCallum, Mark A. Vickers, Sadia Zafreen, Herman Waldmann, Shohei Hori, Sarah L. Gaffen, Neil A. R. Gow, Robert N. Barker, Andrew M. Hall

    Candida albicans remains the fungus most frequently associated with nosocomial bloodstream infection. In disseminated candidiasis, the role of Foxp3+ regulatory T (Treg) cells remains largely unexplored. Our aims were to characterize Foxp3+ Treg‐cell activation in a murine intravenous challenge model of disseminated C. albicans infection, and determine the contribution to disease. Flow cytometric analyses demonstrated that C. albicans infection drove in vivo expansion of a splenic CD4+Foxp3+ population that correlated positively with fungal burden. Depletion from Foxp3hCD2 reporter mice in vivo confirmed that Foxp3+ cells exacerbated fungal burden and inflammatory renal disease. The CD4+Foxp3+ population expanded further after in vitro stimulation with C. albicans antigens (Ags), and included at least three cell types. These arose from proliferation of the natural Treg‐cell subset, together with conversion of Foxp3− cells to the induced Treg‐cell form, and to a cell type sharing effector Th17‐cell characteristics, expressing ROR‐γt, and secreting IL‐17A. The expanded Foxp3+ T cells inhibited Th1 and Th2 responses, but enhanced Th17‐cell responses to C. albicans Ags in vitro, and in vivo depletion confirmed their ability to enhance the Th17‐cell response. These data lead to a model for disseminated candidiasis whereby expansion of Foxp3+ T cells promotes Th17‐cell responses that drive pathology.


  • Production of the effector cytokine interleukin-17, rather than interferon- , is more strongly associated with autoimmune hemolytic anemia

    by A. M. Hall, O. M. Zamzami, N. Whibley, D. P. Hampsey, A. M. Haggart, M. A. Vickers, R. N. Barker

    Interleukin-17A is the signature cytokine of the Th17 subset and drives inflammatory pathology, but its relevance to autoantibody-mediated diseases is unclear. Th1 cells secreting interferon-γ have been implicated in autoimmune hemolytic anemia, so the aim was to determine which cytokine is more closely associated with disease severity. Interferon-γ and interleukin-17A were measured in the sera of patients with autoimmune hemolytic anemia and healthy donors, and in peripheral blood mononuclear cell cultures stimulated with autologous red blood cells, or a panel of peptides spanning red blood cell autoantigen. Serum interleukin-17A, but not interferon-γ, was significantly raised in patients with autoimmune hemolytic anemia (P<0.001), and correlated with the degree of anemia. Interleukin-17A was also more prominent in the responses of peripheral blood mononuclear cells from patients with autoimmune hemolytic anemia to red blood cells, and, again unlike interferon-γ, significantly associated with more severe anemia (P<0.005). There were no interleukin-17A responses to red blood cells by peripheral blood mononuclear cells from healthy donors. Specific autoantigenic peptides were identified that elicit patients' interleukin-17A responses. Interleukin-17A makes a previously unrecognized contribution to the autoimmune response in autoimmune hemolytic anemia, challenging the model that the disease is driven primarily by Th1 cells. This raises the possibility that Th17, rather than Th1, cells should be the target for therapy.


  • Helper T Cells Point the Way to Specific Immunotherapy for Autoimmune Disease

    by Andrew M. Hall, Mark A. Vickers, Robert N. Barker, Lars P. Erwig

    Abstract: Autoimmune haemolytic anaemia (AIHA) is characterised by the production of autoantibodies that target determinants on red blood cells. Current treatments rely on generalised immunosupression or cytotoxic treatments that may have potentially harmful side effects. Whilst the underlying cause of disease remains unknown, recent advances in our understanding of CD4+ helper T cell (Th) subsets that drive and control the autoimmune response have important implications for the development of novel immunotherapy. The effector arm of the adaptive immune response is now known to include at least three Th subsets: Th1, Th2 and the recently described Th17. In human AIHA, the targets of the autoimmune response in most patients, the Rhesus (Rh) proteins, have been identified and sequenced, providing the opportunity to study antigen specific responses. The effector Th response is dominated by Th1 cells that are under the control of IL-10 dependent regulatory cells (Tr1). These Th1 responses can be suppressed, with synthetic peptides that are recognised by the Tr1 cells. Such specificity would provide an extremely potent tool in the treatment of autoimmune disease. This review discusses the recent advances in our understanding of helper T cell subsets and the implications for the development of specific immunotherapy in autoimmune disease, using the well characterised responses in AIHA as an example.